The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.

Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration ...

Arecor Therapeutics announced plans to cease operations within its subsidiary Tetris Pharma during 2025 on Friday, adding ...

The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...

As usage of the medications increases, Circana research indicates deli and produce could be bright spots for spending.

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Financing was co-led by Forbion and General Atlantic, with participants such as RA Capital Management, OrbiMed, and Lilly Asia Ventures.

Metabolic medicines dominated life sciences headlines in 2024, a trend expected to continue into the new year. Other things ...

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or ...

Chinese metabolic diseases specialist Hangzhou Sciwind Biosciences has announced details of a deal with Verdiva Bio for the ...

Clarivate identifies eleven potential blockbuster and transformative drugs in annual Drugs to Watch report: London, UK Friday, January 10, 2025, 14:00 Hrs [IST] Clarivate Plc, a l ...